Q3 2020 Sales Performance

2020 guidance Pharma & Consumer performance on track FY 2020 guidance Sustained recovery in adult vaccination rates Delivering Integration & Restructuring programmes Adjusted EPS Down 1 to 4% CER Tracking to lower end of range Disciplined focus on cost management All expectations and targets regarding future performance should be read together with the "Outlook assumptions and cautionary statement" sections of the Third Quarter 2020 Results Announcement and the cautionary statement slide included with this presentation gsk 80

View entire presentation